Compare REX AI Equity Premium Income ETF (AIPI) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
REX AI Equity Premium Income ETF vs Crispr Therapeutics AG — how do they compare? REX AI Equity Premium Income ETF trades at $37.43, while Crispr Therapeutics AG trades at $54.14 (market cap $5.23B). Which is the better fit depends on your goals.
| AIPI | CRSP | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $44.93 | $76.78 |
52-Week Low | $32.45 | $44.34 |
Market Cap | — | $5.23B |
Enterprise Value | — | $3.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIPI trades at $37.45, up 0.29% with a bullish technical signal from moving averages, though oscillators indicate overbought conditions. The ETF maintains an aggressive weekly dividend distribution strategy yielding approximately 35% annually, supported by its AI-focused equity premium income structure. Recent news highlights the fund's transition to weekly distributions and questions about sustainability of high yields.
The high-yield strategy presents income opportunities but faces structural risks including potential NAV erosion if AI market momentum falters. Analyst sentiment remains cautious due to the capped upside from option-writing strategies and dependency on sustained technology sector performance for distribution sustainability.
CRISPR Therapeutics (CRSP) trades at $53.83, up 0.6% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a Q2 2026 EPS beat with a loss of $0.94 versus an expected $1.19 loss, driven by surging CASGEVY sales. However, financials show deep losses, with a net income margin of -4,101.26% in 2025 and negative operating cash flow, though financing activities provided liquidity.
The outlook is mixed: strong analyst consensus (57.9% buy ratings) and a $82.67 price target reflect optimism around CASGEVY growth and pipeline catalysts, but high valuation (P/S of 466.05) and persistent cash burn pose significant risks. Investment appeal hinges on successful clinical advancements and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About REX AI Equity Premium Income ETF
AIPI provides exposure to leading artificial intelligence firms while seeking to generate monthly income. It uses a covered call strategy to capture premiums from the volatility of AI-related stocks.
Read more on AIPI →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
